Profile data is unavailable for this security.
About the company
Hinova Pharmaceuticals Inc is a Chinese company mainly engaged in the research and development of innovative drugs for critical illnesses. The Company focuses its research on the fields of tumor, metabolic diseases and other critical illnesses. The Company's research platforms include a deuterated drug development platform, a Proteolysis-targeting chimera (PROTAC) technology platform, a targeted drug discovery and validation platform, and a lead compound optimization screening platform. The Company has diversified product portfolios, which are in various clinical test phases, including HC-1119 for prostate cancer, HP501 for hyperuricemia, and HP558 for cancer of the esophagus, among others. The Company conducts clinical tests in domestic and overseas areas.
- Revenue in CNY (TTM)0.00
- Net income in CNY-266.00m
- Incorporated2013
- Employees179.00
- LocationHinova Pharmaceuticals IncCHENGDU 610041ChinaCHN
- Phone+86 2 885058465
- Fax+86 2 885058465
- Websitehttp://www.hinovapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ningbo Menovo Pharmaceutical Co Ltd | 1.23bn | -17.82m | 2.38bn | 2.35k | -- | 1.12 | -- | 1.93 | -0.1115 | -0.1115 | 5.31 | 9.99 | 0.2811 | 1.31 | 6.18 | 523,989.50 | -0.3253 | 4.94 | -0.4782 | 7.83 | 30.72 | 35.39 | -1.16 | 13.71 | 0.7935 | 0.7647 | 0.4042 | 10.78 | -16.51 | 7.46 | -96.58 | -34.53 | -6.03 | -32.54 |
| Henan Taloph Pharmaceutical Stock Co Ltd | 2.01bn | 61.13m | 2.39bn | 2.35k | 40.64 | 1.46 | -- | 1.19 | 0.1024 | 0.1024 | 3.51 | 2.84 | 0.556 | 3.30 | 2.13 | 853,677.20 | 1.72 | 0.272 | 3.55 | 0.4981 | 26.76 | 27.97 | 3.09 | 0.5501 | 0.9283 | 2.02 | 0.3637 | 28.70 | 5.57 | 11.62 | 160.32 | -- | -8.27 | -- |
| Beijing Hotgen Biotech Co Ltd | 454.44m | -26.45m | 2.40bn | 1.04k | -- | 0.7094 | -- | 5.29 | -0.3093 | -0.3093 | 5.14 | 36.65 | 0.1264 | 1.64 | 6.32 | 438,645.70 | -1.04 | 29.65 | -1.11 | 34.70 | 50.71 | 56.08 | -8.25 | 32.26 | 5.50 | -- | 0.0027 | 41.92 | -84.78 | 23.67 | -97.10 | -10.67 | 57.98 | -- |
| Hanshang Group Co Ltd | 1.36bn | 49.62m | 2.41bn | 2.38k | 47.81 | 1.40 | -- | 1.76 | 0.1707 | 0.1707 | 4.65 | 5.84 | 0.3705 | 2.75 | 8.35 | 573,421.20 | 1.16 | 2.00 | 1.92 | 3.89 | 58.35 | 57.24 | 3.13 | 4.89 | 0.3366 | 2.15 | 0.3198 | 15.03 | 0.1893 | 5.14 | -32.24 | 25.62 | 12.88 | -- |
| Chemclin Diagnostics Co Ltd | 455.80m | 150.93m | 2.46bn | 731.00 | 16.31 | 1.78 | -- | 5.40 | 0.3764 | 0.3764 | 1.14 | 3.45 | 0.2684 | 1.02 | 17.03 | 623,526.50 | 8.89 | 11.01 | 9.82 | 12.32 | 74.73 | 74.19 | 33.11 | 31.07 | 5.09 | -- | 0.1518 | 36.64 | -4.28 | 4.00 | -3.44 | -- | 44.10 | -- |
| ChengDu Sheng Nuo Biotec Co Ltd | 457.56m | 72.78m | 2.49bn | 1.13k | 34.12 | 2.77 | -- | 5.44 | 0.651 | 0.651 | 4.09 | 8.00 | 0.3505 | 0.9497 | 4.57 | 405,639.80 | 5.57 | 7.47 | 7.00 | 9.44 | 62.46 | 70.52 | 15.90 | 15.82 | 1.28 | 16.72 | 0.2495 | 21.83 | 9.93 | 9.37 | 9.08 | 18.69 | 54.71 | -- |
| Hinova Pharmaceuticals Inc | 0.00 | -266.00m | 2.50bn | 179.00 | -- | 1.88 | -- | -- | -2.69 | -2.69 | 0.00 | 13.39 | 0.00 | 105.68 | -- | 0.00 | -17.03 | -31.86 | -18.39 | -37.18 | -- | -- | -- | -25,578.24 | 11.83 | -- | 0.0097 | -- | -100.00 | -- | 2.44 | -- | 124.37 | -- |
| Jinan High-tech Development Co Ltd | 555.10m | -119.73m | 2.60bn | 716.00 | -- | 13.36 | -- | 4.69 | -0.1353 | -0.1353 | 0.6275 | 0.2201 | 0.1874 | 0.6198 | 0.6935 | 775,274.40 | -4.46 | -2.99 | -22.92 | -9.42 | 15.19 | 30.52 | -23.79 | -10.84 | 0.5687 | -- | 0.4146 | -- | -58.29 | -13.80 | -618.17 | -- | -35.45 | -- |
Data as of Jun 26 2024. Currency figures normalised to Hinova Pharmaceuticals Inc's reporting currency: Chinese Yuan Renminbi CNY
66.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 4.63m | 20.45% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 3.95m | 17.46% |
| China Fund Management Co., Ltd.as of 31 Dec 2023 | 2.11m | 9.33% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 1.31m | 5.77% |
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 1.04m | 4.59% |
| Changsheng Fund Management Co., Ltd.as of 31 Dec 2023 | 656.18k | 2.90% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 514.40k | 2.27% |
| China Merchants Fund Management Co., Ltd.as of 31 Dec 2023 | 320.70k | 1.42% |
| ABC-CA Fund Management Co., Ltd.as of 31 Dec 2023 | 291.47k | 1.29% |
| Great Wall Fund Management Co., Ltd.as of 31 Dec 2023 | 287.48k | 1.27% |
More ▼
Data from 31 Dec 2023 - 17 Jun 2024Source: FactSet Research Systems Inc.
